Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Sr. VP & Chief Medical Officer | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,982 |
Ending reported balance
After 2022-04-04 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2022-04-01 · Exercise / conversion · Acquired 16,000 · Balance 50,982 Row 2 · 2022-04-01 · Exercise / conversion · Acquired 31,664 · Balance 82,646 Row 3 · 2022-04-01 · Exercise / conversion · Acquired 2,895 · Balance 85,541 Row 4 · 2022-04-01 · Sale · Disposed 8,299 · Balance 77,242 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive. Row 5 · 2022-04-01 · Sale · Disposed 42,260 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive. Row 6 · 2022-04-04 · Exercise / conversion · Acquired 6,285 · Balance 41,267 Row 7 · 2022-04-04 · Exercise / conversion · Acquired 9,625 · Balance 50,892 Row 8 · 2022-04-04 · Exercise / conversion · Acquired 16,875 · Balance 67,767 Row 9 · 2022-04-04 · Sale · Disposed 2,500 · Balance 65,267 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive. Row 10 · 2022-04-04 · Sale · Disposed 18,076 · Balance 47,191 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. Row 11 · 2022-04-04 · Sale · Disposed 3,200 · Balance 43,991 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. Row 12 · 2022-04-04 · Sale · Disposed 9,009 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2025-11-20 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-04-01 · Exercise / conversion · Disposed 16,000 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2026-11-18 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-04-01 · Exercise / conversion · Disposed 31,664 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 6,285 |
Reported balance
After 2022-04-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-04-01 · Exercise / conversion · Disposed 2,895 · Balance 6,285 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 0 |
Reported balance
After 2022-04-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-04-04 · Exercise / conversion · Disposed 6,285 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.57 · Expires 2030-11-20 | Direct | 21,175 |
Reported balance
After 2022-04-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-04-04 · Exercise / conversion · Disposed 9,625 · Balance 21,175 F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.35 · Expires 2029-11-18 | Direct | 13,125 |
Reported balance
After 2022-04-04 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-04-04 · Exercise / conversion · Disposed 16,875 · Balance 13,125 F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
F8: 100% of the shares subject to the option are fully vested and exercisable.
F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,875 | $0.00 Strike: $63.35 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 18 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 16,875 shares Expires 2029-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,625 | $0.00 Strike: $43.57 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 17 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,175 Underlying: Common Stock · 9,625 shares Expires 2030-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,285 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 16 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,285 shares Expires 2027-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 9,009 | $73.42 | $661,440.78 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 12 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,982 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 3,200 | $72.65 | $232,480.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 11 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,991 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 18,076 | $71.71 | $1,296,229.96 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 10 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,500 | $70.56 | $176,400.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 9 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 16,875 | $63.35 | $1,069,031.25 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 8 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 9,625 | $43.57 | $419,361.25 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 7 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 6,285 | $48.52 | $304,948.20 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,895 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 15 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,285 Underlying: Common Stock · 2,895 shares Expires 2027-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,664 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 14 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,664 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · derivative · entry 13 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2025-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 42,260 | $71.32 | $3,013,983.20 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,982 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 8,299 | $70.75 | $587,154.25 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,895 | $48.52 | $140,465.40 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 31,664 | $30.00 | $949,920.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 16,000 | $31.42 | $502,720.00 |
DisclosureSEC source: 0001062993-22-009836 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,481 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · derivative · entry 7 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,481 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 12,481 | $70.07 | $874,543.67 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,982 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 12,481 | $43.46 | $542,424.26 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,339 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,481 Underlying: Common Stock · 24,339 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 100 | $71.06 | $7,106.00 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,982 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 24,239 | $70.26 | $1,703,032.14 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,082 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.97, inclusive. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 24,339 | $43.46 | $1,057,772.94 |
DisclosureSEC source: 0001062993-22-006708 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 02:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 954 | $62.49 | $59,615.46 |
DisclosureSEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,982 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 02:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,936 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 02:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 615 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004516 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,517 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 00:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,336 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001062993-22-001041 · form4.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,664 Underlying: Common Stock · 3,336 shares Expires 2026-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 00:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,200 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001062993-22-001041 · form4.xml · derivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,820 Underlying: Common Stock · 9,200 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 00:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 12,536 | $70.13 | $879,149.68 |
DisclosureSEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.90, inclusive. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 00:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 3,336 | $30.00 | $100,080.00 |
DisclosureSEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2022 Filed Jan 14, 2022 00:54 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 9,200 | $43.46 | $399,832.00 |
DisclosureSEC source: 0001062993-22-001041 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,773 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · derivative · entry 12 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,180 Underlying: Common Stock · 4,773 shares Expires 2027-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · derivative · entry 11 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,020 Underlying: Common Stock · 8,750 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 201 | $90.17 | $18,124.17 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 10 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,902 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.25, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 899 | $89.33 | $80,307.67 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 9 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,103 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.02 to $89.88, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 900 | $88.31 | $79,479.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 8 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,002 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.01 to $88.90, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,500 | $87.60 | $131,400.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 7 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,902 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $87.92, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,700 | $86.45 | $233,415.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,402 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.03 to $86.91, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 5,736 | $85.49 | $490,370.64 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,102 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.98, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,587 | $84.81 | $134,593.47 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,838 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.43 to $84.98, inclusive. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 4,773 | $48.52 | $231,585.96 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 8,750 | $43.46 | $380,275.00 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 842 | $87.68 | $73,826.56 |
DisclosureSEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,902 F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:43 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 28,400 | $0.00 Strike: $75.33 | $0.00 |
DisclosureSEC source: 0001062993-21-011509 · form4.xml · derivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 Underlying: Common Stock · 28,400 shares Expires 2031-11-19 F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021). Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:43 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011509 · form4.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,744 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 00:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,547 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001177648-21-000029 · edgar.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 9,547 shares Expires 2027-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017). Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 00:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 100 | $86.21 | $8,621.00 |
DisclosureSEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 00:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 7,495 | $85.02 | $637,224.90 |
DisclosureSEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,044 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.